TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18242045
Drug: Anti-TNF molecules
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF molecules
Study: 10452624
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine with three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Study: 10452624
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine and three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Study: 10452624
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections
Study: 8591095
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with additional group work
Study: 8591095
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without group work
Study: 8591095
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mothers
Study: 8591095
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for children
Study: 2669345
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (saline wet‐to‐dry compressive dressing)
Study: 31586420
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg no load
Study: 29228792
Drug: Mixed herbal
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed herbal formulation (Silybum marianum, Urtica dioica, Boswellia serrata) for 90 days
Study: 25446887
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous (IV) calcifediol (450μg)
Study: 25446887
Drug: Oral modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral modified-release (MR) calcifediol (450 or 900μg)
Study: 22836514
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g PL/day
Study: 22836514
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g PL/day
Study: 22836514
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g PL/day + 2 g PSt/day
Study: 18316290
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (4 two-hour weekly sessions)
Study: 17080927
Drug: New candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: New candidate therapy for neuropathic pain
Study: 14597641
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg aliskiren
Study: 14597641
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aliskiren
Study: 14597641
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aliskiren
Study: 9607383
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losartan
Study: 8828996
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg nightly for 7-10 nights
Study: 30672194
Drug: Neurological routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological routine treatment and western medicine rehabilitation therapy (Control)
Study: 18521538
Drug: Isosorbide-5-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (5-ISMN) 30 mg three times daily for 7 days
Study: 10561255
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (IFNalpha2a) administered three times weekly at 18 x 10(6) IU
Study: 10561255
Drug: Interleukin‐2 (IL‐2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin‐2 (IL‐2) administered as a continuous intravenous infusion for 5 days (18 x 10(6) IU/m(2)/d)
Study: 10561255
Drug: Cross-over treatment
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over treatment after failure of IL-2 or IFNalpha2a
Study: 8547958
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose IL-2 (4.5 million IU/day, 3 times weekly for 6 months)
Study: 8547958
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose IL-2
Study: 29972904
Drug: 65 μm
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 μm glycine powder air-polishing (GPAP) therapy
Study: 29972904
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling plus polishing paste therapy (Control)
Study: 21464041
Drug: Insulin >6.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin >6.10 μU/ml
Study: 21464041
Drug: Insulin <2.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin <2.75 μU/ml
Study: 21464041
Drug: Insulin 2.75-4.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 2.75-4.10 μU/ml
Study: 21464041
Drug: Insulin >6.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin >6.10 μU/ml with viral load <4.39 log(10) copies/ml
Study: 21464041
Drug: Higher insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher insulin levels
Study: 380606
Drug: Alprenolol 200
Normalized name: alprenolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol 200 mg b.i.d.
Study: 28095787
Drug: Additional functional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional functional training as part of the habitual daily routine during short term stays at nursing homes after discharge from hospital.
Study: 25588095
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence skills training (MST)
Study: 23449357
Drug: Mf (MMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mf (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 3 months)
Study: 23449357
Drug: MFP (MMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 12 months with 6 monthly infusions of 60 mg m(‐2) of cisplatin)
Study: 21150915
Drug: Tryptophan (TRP)
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan (TRP) augmentation
Study: 18808413
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg biw
Study: 17378197
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of indometacin entric-coater tablets
Study: 8040603
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fish oil daily for 3 or 6 months (containing 18% eicosapentaenoic acid and 12% docosahexaenoic acid)
Study: 8040603
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fish oil daily for 3 or 6 months
Study: 3055324
Drug: Tenoretic 100
Normalized name: Tenoretic 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoretic 100 (atenolol 100 mg; chlorthalidone 25 mg)
Study: 3055324
Drug: Tenoretic 50
Normalized name: Tenoretic 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoretic 50 (atenolol 50 mg; chlorthalidone 25 mg)
Study: 31268555
Drug: Staccato alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staccato alprazolam 1.0 mg
Study: 31268555
Drug: Staccato alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staccato alprazolam 2.0 mg
Study: 29792052
Drug: CBT4CBT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT with brief weekly monitoring
Study: 24099551
Drug: Suboxone tablets
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suboxone tablets (8/2mg)
Study: 24099551
Drug: Suboxone tablets
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suboxone tablets and films
Study: 21377898
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (6 μg hemagglutinin per strain)
Study: 21377898
Drug: Intramuscular vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccine (15 μg hemagglutinin per strain)
Study: 9314448
Drug: Intramuscular vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccine
Study: 9695720
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole once daily for 4 days
Study: 11372588
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo once daily for 4 days
Study: 9589673
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH treatment
Study: 27475670
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated radiation therapy (MHRT) - 62 Gy in 20 fractions over 5 weeks
Study: 27475670
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (CFRT) - 80 Gy in 40 fractions over 8 weeks
Study: 25431225
Drug: Qishenyiqi Dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishenyiqi Dripping Pills
Study: 11818981
Drug: Paico juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paico juice (1 ml/Kg for <10 Kg, 2 ml/Kg for >10 Kg, one dose before breakfast for three consecutive days)
Study: 11818981
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg for >5 years, 200 mg for <5 years, single dose)
Study: 10194990
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion (1.1 micrograms/kg/h for 75 hours)
Study: 7917782
Drug: Proximal site
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal site perfusion of paracetamol
Study: 7917782
Drug: Distal site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal site perfusion of paracetamol
Study: 31547675
Drug: Rapeseed meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed meal (RSM) and maize gluten (MG)
Study: 29211951
Drug: 2.6% edathamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6% edathamil gel (Livionex® Dental Gel)
Study: 25266794
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L hydroxyethyl starch 6% 130/0.42 (Group T)
Study: 25266794
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L Ringer's lactate (Group R/L)
Study: 22161540
Drug: ColoPlus® (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ColoPlus® (50 g twice a day for 4 weeks)
Study: 22161540
Drug: Standard anti-diarrhea
Normalized name: loperamide hydrochloride Oral Solution [Anti-Diarrhea]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-diarrhea treatment alone
Study: 17115349
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) + human isophane insulin (NPH)
Study: 11530155
Drug: Culturally-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally-based health promotion programme introduced in 1981, details on dosage and duration not applicable.
Study: 7756706
Drug: Gentamicin 2
Normalized name: gentamicin 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2 mg/kg
Study: 9145878
Drug: Gentamicin 7
Normalized name: gentamicin 70 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 7 mg/kg
Study: 8198053
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (900 mg d-alpha-tocopherol/d)
Study: 30194502
Drug: Combination HIV-prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV-prevention and microfinance intervention including HIV-risk reduction, financial-literacy training, vocational training, and a matched-savings program.
Study: 27838190
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with vigabatrin
Study: 30236380
Drug: Initial control
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial control of spasms between days 14 and 42 of treatment
Study: 30236380
Drug: Increasing lead-time
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing lead-time to treatment
Study: 27772740
Drug: Prolonged-release fampridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release fampridine (10mg, twice daily)
Study: 23306418
Drug: CoQ10 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (200 mg daily)
Study: 20881069
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg ZnO/d for 5 d/wk)
Study: 20881069
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mg glucose)
Study: 18594845
Drug: 5-FU/oxaliplatin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/oxaliplatin-based chemotherapy (FUFOX vs. CAPOX)
Study: 12846707
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.1 mg.kg‐1 postinduction (EP group, n = 25)
Study: 12846707
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion at 0.02 mg.kg‐1.h‐1 following 0.05 mg.kg‐1 bolus (INF group, n = 25)
Study: 6088819
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg capsules orally five times daily for ten days
Study: 6088819
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules orally five times daily for ten days
Study: 6088819
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg capsules
Study: 23147696
Drug: JTT-751 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT-751 (1.5 g/day)
Study: 23147696
Drug: JTT-751 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT-751 (3 g/day)
Study: 23147696
Drug: JTT-751 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT-751 (6 g/day)
Study: 17526169
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang Soft Capsule (LDSC) plus Ginkgo Leaf Tablet (GLT)
Study: 9437777
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (5.1%, 5/98 positive for C. trachomatis)
Study: 9437777
Drug: Multidose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose therapy compliance (94.5% among 73 women)
Study: 31318832
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate administration
Study: 26075538
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months
Study: 1539754
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 micrograms/kg body weight) given once every three months for four, eight, or eleven doses
Study: 2951792
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenoterol and ipratropium bromide
Study: 28676038
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil
Study: 31095126
Drug: Normobaric interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric interval hypoxic therapy and enteral oxygen therapy
Study: 22939108
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg/kg
Study: 18602726
Drug: TIV from
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV from multi‐dose vials with thimerosal
Study: 15354456
Drug: 0.42% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42% fluoride gel
Study: 15354458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fluoride gel)
Study: 8497343
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) sequentially combined with 10 mg of medroxyprogesterone acetate
Study: 3305088
Drug: Triamterene (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (potassium blocking agent)
Study: 29338855
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily vaginal Endometrin
Study: 29338855
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily intramuscular P only
Study: 29338855
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily Endometrin plus 50 mg intramuscular P every 3rd day
Study: 26908758
Drug: Intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal metronidazole (750 mg) plus miconazole (200 mg) for 5 consecutive nights each month for 12 months
Study: 24751822
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 1000 mg iron
Study: 23412930
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25mg daily (n = 58)
Study: 16834833
Drug: Chlorpheniramine 6
Normalized name: carbetapentane-chlorpheniramine 60 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 6 mg
Study: 3446535
Drug: No ALT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ALT treatment following PI or LI
Study: 29645341
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg once daily)
Study: 20346182
Drug: 0.03 IU/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 IU/min vasopressin infusion
Study: 20214761
Drug: Artesunate-amodiaquine (Camoquin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet
Study: 15585538
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (10 sessions over five months)
Study: 12391340
Drug: Low-flow ventriculoperitoneal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow ventriculoperitoneal shunt treatment
Study: 10518856
Drug: Dental floss
Normalized name: dental floss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental floss containing 0.25 mg tetrasodium pyrophosphate per cm
Study: 8077370
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol administration (100 micrograms)
Study: 1228009
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate in a cream base containing DMSO
Study: 11327066
Drug: One-stage full-mouth
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage full-mouth (OSFM) disinfection treatment
Study: 29992831
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg once daily
Study: 29992831
Drug: MPFF 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 500 mg twice daily
Study: 27129012
Drug: Olokizumab administered
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olokizumab administered intravenously (iv) or subcutaneously (sc)
Study: 22744665
Drug: Fipamezole 90
Normalized name: Fipamezole
DrugBank: Fipamezole (DB06585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fipamezole 90 mg TID
Study: 19639377
Drug: Purified black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified black tea theaflavins (TFs) providing 77.5 mg
Study: 19639377
Drug: Purified black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified black tea theaflavins/catechins (TFs/catechins) providing 75.0 mg TFs plus 150.0 mg catechins and 195.0 mg of other polyphenols
Study: 17923296
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy exercises after carpal tunnel release
Study: 17923296
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy exercises plus therapist-directed program for 2 weeks
Study: 19330802
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day)
Study: 12196367
Drug: Usual information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual information treatment options
Study: 10381769
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg MDMA